{"prompt": "['Protocol RS-001', 'Confidential', 'In an ongoing phase 1 clinical study of ABI-009 in participants with severe pulmonary arterial', 'hypertension (PAH-001), rapamycin blood levels one week after IV ABI-009 administration are', 'available from 3 participants. The whole blood trough rapamycin levels are within the range of', '4.3-9. 1 ng/ml for the 5 mg/m2/week ABI-009 dose and 7.3-17.5 ng/ml for the 10 mg/m2/week', 'dose, in general agreement with the PK modeling. Although there is no pediatric PK data with', 'ABI-009 currently available, overall the current dose escalation scheme is justified based on', 'existing and predicted adult clinical PK data.', 'The planned ABI-009 weekly starting dose levels in this study are lower than the previous dose', 'of everolimus in similar clinical settings. In EXIST-3, a double-blind placebo-controlled study', 'evaluating everolimus as an adjunctive therapy for treatment-resistant focal-onset seizures in', 'TSC with mostly pediatric participants [124], the median dose received by participants in the', 'everolimus low-exposure group was 5.2 mg/m2/day (range 13-14.5) and the median whole blood', 'rapamycin trough level (Cmin) observed at the end of the core phase was 5.1 ng/mL (1.4-25.3),', 'whereas in the high-exposure group the median dose was 7.5 mg/m2/day (1.4-24.4) and the', 'median Cmin was 8.3 ng/mL (0.8-22.0).', 'Figure 1:', 'Tumor Volume and Animal Survival following Treatment with IV ABI-009', 'and Oral mTOR Inhibitors', '2000', '1500', 'Saline', 'Rapa (PO, 3 mg/kg, 5x/wk)', '1000', 'Evero (PO, 3 mg/kg, 5x/wk)', 'ABI-009 (IV, 7.5 mg/kg, 2x/wk)', '500', '0', '0', '10', '20', '30', '40', 'Treatment Days', '100', '- Saline', '-', 'Rapa (PO, 3 mg/kg, 5x/wk)', '50', '- Evero (PO, 3 mg/kg, 5x/wk)', 'ABI-009 (IV, 7.5 mg/kg, 2x/wk)', '0', '0', '10', '20', '30', '40', 'Treatment Days', 'Due to its different PK profile, ABI-009 can achieve greater drug exposure than oral mTOR', 'inhibitors at the same dose level. Consistent with this PK observation, preclinical study results', 'also demonstrate significantly greater antitumor activity and prolonged survival with ABI-009', 'administered IV compared with equal weekly dosing of oral rapamycin and oral everolimus', '(AADi internal data). In athymic mice bearing UMUC3 human bladder cancer xenografts, ABI-', '009 was administered IV at 7.5 mg/kg, twice weekly (total weekly dose: 15 mg/kg), whereas', 'rapamycin and everolimus were administered PO at 3 mg/kg/day, 5 days per week to achieve the', 'same weekly total dose. The tumor growth inhibition (TGI) was 69.6% with ABI-009,', 'significantly greater than oral rapamycin (TGI 24.3%; p < 0.00001 VS ABI-009, ANOVA) and', 'Version 2', 'Version Date: October 31, 2018', 'Page 29 of 72']['Protocol RS-001', 'Confidential', 'oral everolimus (TGI 36.2%; p = 0.0023 VS ABI-009, ANOVA). The median overall survival', 'was also significantly longer with ABI-009 (not reached) compared with oral rapamycin (21', 'days; p < 0.05, log rank test) and oral everolimus (19 days; p < 0.05, log rank test). Results from', 'this preclinical study clearly demonstrate superior therapeutic efficacy of ABI-009 to oral mTOR', 'inhibitors.', '1.14', 'Distribution of ABI-009 in the Brain', 'Albumin has been shown to be able to penetrate the blood-brain barrier (BBB) and distribute in', 'the brain. Preclinical and clinical studies demonstrate the usefulness of albumin and albumin-', 'bound drugs in the treatment of glioblastoma. In a clinical study, intravenous administration of 5-', 'aminofluorescein-labeled albumin 0.5-4 days prior to surgery at 0.5-1 mg/kg in 13 participants', 'resulted in the fluorescent visualization of malignant gliomas in 11 participants (84%), which', 'facilitated the complete resection of glioblastoma in 9 participants (69%) [148] In an orthotopic', 'mouse GBM xenograft model, albumin-linked aldoxorubicin but not doxorubicin significantly', 'delayed tumor growth and prolonged survival. In a Phase 2 study of participants with recurrent', 'GBM, aldoxorubicin treatment resulted in 3 PR, 7 SD, and 11 PD in 21 participants [149].', 'As an albumin-bound nanoparticle, ABI-009 is potentially a suitable treatment option for disease', 'indications in the brain, including epilepsy. In a biodistribution study in rats, radiolabeled ABI-', '009 showed significant brain uptake at 5 days (AADi internal data). As shown in Figure 2, the', 'radioactivity accumulation in the brain was comparable to all other major organs 5 days after a', 'single IV dose of radiolabeled ABI-009.', 'Figure 2:', 'Distribution of Radioactivity in Tissues in Male Rats', '4.0', 'Male Rats', '3.5', '3.0', 'T', '2.5', '2.0', 'T', 'T', 'I', '1.5', 'I', 'I', 'I', '1.0', 'T', '0.5', 'I', '0.0', 'Version 2', 'Version Date: October 31, 2018', 'Page 30 of 72']\n\n###\n\n", "completion": "END"}